Microbio Co., Ltd. Announces Promising Results of “MS-20” as an Add-on Therapy for Ulcerative Colitis
TAIPEI, March 17, 2025 /PRNewswire/ -- Microbio Co., Ltd. (TPEx: 4128) today announced promising results from an exploratory clinical trial assessing MS-20 in combination with current medications for ulcerative colitis


